Obesity Clinical Trial
Official title:
Diet-induced Thermogenesis in Patients With Postoperative RYGBP Weight Regain
Introduction: According to the National Health and Nutrition Examination Survey 2009-2010,
78 million American adults are obese. Bariatric surgery can provide for a sustained
long-term weight loss and the metabolic change caused by the surgery seems to be the main
cause of this loss. Cross-sectional, prospective and experimental studies, carried out
during the post-operative period of Roux-en-Y Gastric Bypass surgery (RYGBP) have shown an
increase of over 200% in energy expenditure after meals Diet-induced Thermogenesis (DIT), a
specific component of energy expenditure) when compared with obese patients. However,
despite this metabolic improvement, 20-50% of the patients can suffer weight regain about 2
years after surgery. So one question whether such metabolic benefits remain active following
post-operative weight regain, or if the disappearance or decrease of these metabolic
benefits may be seen as causes of this weight regain.
Objective:To evaluate whether there are DIT differences between patients who maintained
weight loss and those who regained weight in the late postoperative (postop) period of RYGBP
and those who continue with preoperative (preop) obesity.
Methods: This cross-sectional study evaluated three female groups: 1) Postop RYGBP patients
operated at least 2 years previously, with healthy weight (at least 50% loss of excess
weight) - HW group ; 2) Clinically severe obese patients (BMI > 40 kg/m2, without
co-morbidities or > 35 kg/m2 with co-morbidities) - OB group; 3) Post-op RYGBP WR patients
(at least 10% above post-op minimum weight and less than 50% loss of preop excess weight) -
WR group. All patients, from a private practice in Brasilia, were given indirect calorimetry
examinations (GERATHERM RESPIRATORY®) measuring resting metabolic rate (RMR), respiratory
exchange rate (RER) and DIT and collected urine during 24 hours for analysis. Immediately
after RMR measurement, a solid mixed meal was served (270 kcal: 62% carbohydrate, 12%
protein and 26% lipid). Remove? After ten minutes, successive PP energy expenditure
measurements were taken (after some minutes, viz): 10-20, 20-30, 30-40, 60-70, 70-80, 80-90,
110-120, 120- 130, 130-140, 160-170 and 170-180, accompanying a 3-hour measurement period.
DIT, calculated for each interval, followed this equation: DIT = PP Metabolic rate (MR) time
interval - RMR. Correct? Mean areas under the curve (AUC) of all groups and baseline time
measurements were compared using the analysis of variance test (ANOVA). Between-group
longitudinal changes were tested using a mixed-effects model analysis of variance for
repeated measures. Showing a p-value < 0.05, a Bonferroni correction was used. AUC was
calculated by trapezoidal rule, considering significant a value of p <0.05.
Results: 45 patients participated (HW 21, OB 13, WR 11). Mean group age was 37.00 ± 6.98
years , 38.72 ± 7.01 years, and 37.88 ± 6.39 years, respectively. I changed the sequence to
match the original. RER values increased significantly in all groups from baseline until
final measurements. Metabolic rate (MR) adjusted for body weight (BW-adjusted MR (MR/kg)?)
was not significant in the OB group at any PP moment compared to baseline. The HW and WR
groups showed significant increase until final measurements. Mean AUC values for RER and RMR
in absolute terms did not differ between groups (p = 0.3111 and p = 0.1131, respectively).
(Two p values for how many groups ? 2 or 3?) Mean AUC values for BW-adjusted MR (kcal/kg)?
differed between groups, where the average AUC value was significantly greater in the HW
group than in the WR and the OB groups (p <0.0001 for both). Mean AUC value for BW-adjusted
MR in the WR group was not significantly different from the OB group (p = 0.6369).
;
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |